Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Chronic myelogenous leukemia (CML) treatment has been transformed by molecularly targeted therapies.
• The BCR-ABL fusion oncogene is a key driver of CML, and its tyrosine kinase activity is a target for novel therapeutics.

Purpose of the Study:

• To review the current landscape of CML treatment.
• To highlight the importance of diagnosis, molecular monitoring, and resistance mutation identification.
• To provide guidance on monitoring patients treated with tyrosine kinase inhibitors.

Main Methods:

• Literature review of CML treatment strategies.
• Discussion of diagnostic and monitoring techniques.
• Analysis of drug resistance mechanisms and patient management.

Main Results:

• Tyrosine kinase inhibitors targeting BCR-ABL have dramatically improved CML outcomes.
• Accurate diagnosis and molecular monitoring are crucial for successful CML management.
• Identification of resistance mutations is essential for optimizing patient treatment.

Conclusions:

• Molecularly targeted therapy represents a paradigm shift in CML treatment.
• Comprehensive patient monitoring, including molecular profiling, is vital for long-term disease control.
• Understanding and managing drug resistance are key to sustained therapeutic success in CML.